<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2000">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634256</url>
  </required_header>
  <id_info>
    <org_study_id>INs-LF-CURCUMA</org_study_id>
    <nct_id>NCT01634256</nct_id>
  </id_info>
  <brief_title>A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed a double-blind parallel study in a group of showing mild hepatic
      injury subjects who were given Fermented turmeric over a period of 12 weeks. The
      investigators measured liver function parameters , including ALT(Alanine Transaminase),
      AST(Aspartate Transaminase), ALP(Alkaline Phosphatase), γ-GT(Gamma-Glutamyl Transferase),
      and serum bilirubin, and monitored their blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in ALT(Alanine Transaminase)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ALT was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in AST(Aspartate Transaminase)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AST was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALP(Alkaline Phosphatase)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ALP was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in γ-GT(Gamma-Glutamyl Transferase)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>γ-GT was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Bilirubin</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>serum bilirubin was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mild Hepatic Injury</condition>
  <arm_group>
    <arm_group_label>Fermented turmeric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo(3.0g/day)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented turmeric</intervention_name>
    <description>Fermented turmeric(3.0g/day)</description>
    <arm_group_label>Fermented turmeric</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 19-70 years old

          -  Mild hepatic injury as indicated by ALT(Alanine Transaminase) level ≥ 40

          -  Able to give informed consent

        Exclusion Criteria:

          -  Allergy or hypersensitivity to any of the ingredients in the test products

          -  History of reaction to any of the experimental products or of gastrointestinal
             diseases such as Crohn's disease or gastrointestinal surgery

          -  Carriers of viral hepatitis (type B and C)

          -  History of underlying Esophageal varices, hepatic encephalopathy, ascites(past 12
             months)

          -  Participation in other clinical trials within the past 2 months

          -  Patients with acute hepatitis (type B and C)

          -  History of underlying cirrhosis and liver cancer

          -  History of underlying biliary diseases such as jaundice or gallstones

          -  History of underlying kidney disease such as Chronic renal failure or nephrotic
             syndrome

          -  Pregnant, planning to become pregnant, or breast-feeding

          -  Laboratory test, medical or psychological conditions deemed by the investigators to
             interfere with successful participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Wook Kim, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 4, 2012</lastchanged_date>
  <firstreceived_date>July 3, 2012</firstreceived_date>
  <firstreceived_results_date>July 11, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Turmeric extract</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 19 to 70 years, ALT levels ≥ 40IU/L subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fermented Turmeric</title>
          <description>Fermented turmeric(3times/day, 6capsules/day, 3g/day) for 12weeks
Fermented curcuma : Powdered Curcuma longa L., was produced through the fermentation of Aspergillus oryzae to 25 ˚ C for 36 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo(3times/day, 6capsules/day, 3g/day) for 12weeks
Placebo : Amount and calorie of placebo are same with Fermented turmeric.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fermented Curcuma</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.03" spread="8.53"/>
                <measurement group_id="B2" value="36.17" spread="7.42"/>
                <measurement group_id="B3" value="37.60" spread="8.06"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in ALT(Alanine Transaminase)</title>
        <description>ALT was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Turmeric</title>
            <description>Oral intake Fermented turmeric (3.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(3.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in ALT(Alanine Transaminase)</title>
            <description>ALT was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.08" spread="25.10"/>
                  <measurement group_id="O2" value="55.68" spread="15.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44.92" spread="15.47"/>
                  <measurement group_id="O2" value="53.82" spread="26.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in AST(Aspartate Transaminase)</title>
        <description>AST was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Turmeric</title>
            <description>Oral intake Fermented turmeric (3.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(3.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in AST(Aspartate Transaminase)</title>
            <description>AST was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.27" spread="13.80"/>
                  <measurement group_id="O2" value="35.59" spread="8.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.96" spread="7.96"/>
                  <measurement group_id="O2" value="34.77" spread="10.87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALP(Alkaline Phosphatase)</title>
        <description>ALP was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Turmeric</title>
            <description>Oral intake Fermented turmeric (3.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(3.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in ALP(Alkaline Phosphatase)</title>
            <description>ALP was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.04" spread="19.33"/>
                  <measurement group_id="O2" value="71.73" spread="13.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80.04" spread="21.98"/>
                  <measurement group_id="O2" value="68.95" spread="13.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in γ-GT(Gamma-Glutamyl Transferase)</title>
        <description>γ-GT was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Turmeric</title>
            <description>Oral intake Fermented turmeric (3.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(3.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in γ-GT(Gamma-Glutamyl Transferase)</title>
            <description>γ-GT was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.31" spread="71.49"/>
                  <measurement group_id="O2" value="104.2" spread="69.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.96" spread="45.63"/>
                  <measurement group_id="O2" value="100.77" spread="68.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Bilirubin</title>
        <description>serum bilirubin was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Turmeric</title>
            <description>Oral intake Fermented turmeric (3.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(3.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Serum Bilirubin</title>
            <description>serum bilirubin was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.98" spread="0.46"/>
                  <measurement group_id="O2" value="0.89" spread="0.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" spread="0.38"/>
                  <measurement group_id="O2" value="0.84" spread="0.26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Fermented Curcuma</title>
          <description>Oral intake fermented curcuma (3.0g/day) for 12weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral intake placebo(3.0g/day) for 12weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sang-Wook Kim, MD</name_or_title>
      <organization>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</organization>
      <phone>82-63-276-8284</phone>
      <email>clickm@jbnu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
